20627987

Source:http://linkedlifedata.com/resource/pubmed/id/20627987

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0796392, umls-concept:C1566537
pubmed:dateCreated	2010-7-14
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8900488
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab, http://linkedlifedata.com/resource/pubmed/chemical/ranibizumab
pubmed:status	MEDLINE
pubmed:issn	1468-5833
pubmed:author	pubmed-author:Bertele'VittorioV, pubmed-author:GarattiniSilvioS
pubmed:issnType	Electronic
pubmed:volume	341
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	c3721
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:20627987-Angiogenesis Inhibitors, pubmed-meshheading:20627987-Antibodies, Monoclonal, pubmed-meshheading:20627987-Antibodies, Monoclonal, Humanized, pubmed-meshheading:20627987-Humans, pubmed-meshheading:20627987-Macular Degeneration
pubmed:year	2010
pubmed:articleTitle	Bevacizumab and ranibizumab. A matter of public interest.
pubmed:publicationType	Letter